CervoMed Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>CervoMed Inc. invites stockholders to its virtual 2024 Annual Meeting on June 14, 2024, to vote on director elections, auditor ratification, and executive compensation.</b>

AI Summary

CervoMed Inc. (CRVO) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. CervoMed Inc. will hold its 2024 Annual Meeting of Stockholders on June 14, 2024, at 1:00 p.m. ET. The meeting will be conducted virtually via live webcast, allowing remote participation. Stockholders will vote on the election of eight directors to the board. The appointment of RSM US LLP as the independent registered public accounting firm for FY2024 will be ratified. An advisory vote will be held on the compensation of named executive officers for the year ended December 31, 2023.

Why It Matters

For investors and stakeholders tracking CervoMed Inc., this filing contains several important signals. The virtual format allows broader participation from stockholders regardless of location. Key governance matters, including board composition and executive pay, are subject to stockholder approval.

Risk Assessment

Risk Level: low — CervoMed Inc. shows low risk based on this filing. The filing is a routine DEF 14A proxy statement with no new financial or operational disclosures, indicating low immediate risk.

Analyst Insight

Stockholders should review the proxy materials to make informed voting decisions on director nominees, auditor ratification, and executive compensation.

Executive Compensation

Key Numbers

• 8 — Directors (to be elected at the annual meeting)
• June 14, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
• 1:00 p.m. ET — Annual Meeting Time (2024 Annual Meeting of Stockholders)
• December 31, 2023 — Executive Compensation Period (year ended December 31, 2023)
• December 31, 2024 — Fiscal Year End (fiscal year ending December 31, 2024)

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• RSM US LLP (company) — independent registered public accounting firm
• John Alam, M.D. (person) — President & Chief Executive Officer
• June 14, 2024 (date) — Annual Meeting date
• 2024 (date) — Annual Meeting year
• 2023 (date) — executive compensation year
• 2024 (date) — fiscal year for accounting firm

FAQ

Industry Context

CervoMed Inc. operates in the pharmaceutical preparations industry. This filing is a standard proxy statement for an annual shareholder meeting.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, requiring public companies to provide shareholders with information before their annual meetings.

What Investors Should Do

1. Review the list of director nominees and their qualifications.
2. Evaluate the ratification of RSM US LLP as the independent auditor.
3. Consider the advisory vote on the compensation of named executive officers.

Key Dates

• 2024-06-14: 2024 Annual Meeting of Stockholders — Key date for voting on board members, auditor, and executive compensation.
• 2024-04-29: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine proxy statement and does not contain comparative financial data from a previous filing.

Key Financial Figures

• $0.001 — f the Company's common stock, par value $0.001 per share ("common stock"), at a ratio
• $149.4 m — e gross proceeds of up to approximately $149.4 million, announced March 28, 2024, and co
• $0 — mmon Stock the common stock, par value $0.001, of EIP issued and outstanding prio

Filing Documents

• crvo20240425_def14a.htm (DEF 14A) — 550KB
• a01.jpg (GRAPHIC) — 13KB
• crvo01.jpg (GRAPHIC) — 255KB
• crvo02.jpg (GRAPHIC) — 181KB
• crvo20240425_def14aimg004.jpg (GRAPHIC) — 6KB
• crvo20240425_def14aimg005.jpg (GRAPHIC) — 17KB
• crvo20240425_def14aimg006.jpg (GRAPHIC) — 17KB
• logosm.jpg (GRAPHIC) — 10KB
• logosmr.jpg (GRAPHIC) — 8KB
• 0001437749-24-013681.txt (&nbsp;) — 1249KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 22 PROPOSAL NO. 3: ADVISORY VOTE ON EXECUTIVE COMPENSATION 27 DIRECTOR COMPENSATION 28

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 30 PAY VERSUS PERFORMANCE 33 EQUITY COMPENSATION PLAN INFORMATION 36 CERTAIN RELATIONSHIPS AND RELATED PARTY INFORMATION 37 OTHER MATTERS 38 INTRODUCTORY NOTES Note Regarding Company References and Other Defined Terms As previously disclosed in our Current Report on Form 8-K filed on August 17, 2023 with the SEC, on August 16, 2023, the Delaware corporation formerly known as "Diffusion Pharmaceuticals Inc." completed a merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger, dated March 30, 2023 (the "Merger Agreement") by and among Diffusion Pharmaceuticals Inc. ("Diffusion"), Dawn Merger Inc., a wholly-owned subsidiary of Diffusion ("Merger Sub") and EIP Pharma, Inc. ("EIP"), pursuant to which Merger Sub merged with and into EIP, with EIP surviving the Merger a wholly-owned subsidiary of Diffusion (the "Merger"). Additionally, on August 16, 2023, Diffusion changed its name from "Diffusion Pharmaceuticals Inc." to "CervoMed Inc." Prior to the Effective Time (as defined below), in connection with the transactions contemplated by the Merger Agreement, Diffusion effected a reverse stock split of the Company's common stock, par value $0.001 per share ("common stock"), at a ratio of 1-for-1.5 (the "Reverse Stock Split"). At the Effective Time, each outstanding share of EIP capital stock was converted into the right to receive 0.1151 shares of Company common stock. For accounting purposes, the Merger is treated as a reverse recapitalization under U.S. generally accepted accounting principles and EIP is considered the accounting acquirer. Accordingly, EIP's historical results of operations are deemed the Company's historical results of operations for all periods prior to the Merger and, for all periods following the Merger, the results of operations of the combined company will be included in the Company's financial statements. Following the compl

View Full Filing

View this DEF 14A filing on SEC EDGAR